Obinutuzumab as a primary anti-CD20 agent in pediatric frequently relapsing and steroid-dependent nephrotic syndrome.

IF 2.5 3区医学 Q1 PEDIATRICS

Pediatric Nephrology Pub Date : 2026-12-01 Epub Date: 2026-07-07 DOI:10.1007/s00467-026-07425-0

Ancuta Caliment, Emmanuelle Andlauer, Sara Macchi, Olivier Niel

{"title":"Obinutuzumab as a primary anti-CD20 agent in pediatric frequently relapsing and steroid-dependent nephrotic syndrome.","authors":"Ancuta Caliment, Emmanuelle Andlauer, Sara Macchi, Olivier Niel","doi":"10.1007/s00467-026-07425-0","DOIUrl":null,"url":null,"abstract":"Background: Idiopathic nephrotic syndrome (INS) is the leading glomerular disease in children, often responding well to steroids. However, frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS) require the introduction of steroid-sparing agents to mitigate steroid toxicity.Methods: This retrospective, pilot study including 6 patients with FRNS or SDNS assessed the efficacy and safety of obinutuzumab as a first line of anti-CD20 therapy.Results: Using one dose of obinutuzumab, complete remission was achieved in all 6 patients within 11 months. Remission rate was 100% up to 12 months post-injection, and 80% at both 24 and 56 months. Infusion-related reactions occurred in 83% of the patients, primarily mild and transient; one patient required immunoglobulin supplementation but no severe infections were noted.Conclusions: These preliminary results suggest that obinutuzumab is a promising first-line anti-CD20 therapy for FRNS and SDNS in children, offering sustained remission with a good safety profile.","PeriodicalId":19735,"journal":{"name":"Pediatric Nephrology","volume":" ","pages":"4525-4530"},"PeriodicalIF":2.5000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00467-026-07425-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Idiopathic nephrotic syndrome (INS) is the leading glomerular disease in children, often responding well to steroids. However, frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS) require the introduction of steroid-sparing agents to mitigate steroid toxicity.

Methods: This retrospective, pilot study including 6 patients with FRNS or SDNS assessed the efficacy and safety of obinutuzumab as a first line of anti-CD20 therapy.

Results: Using one dose of obinutuzumab, complete remission was achieved in all 6 patients within 11 months. Remission rate was 100% up to 12 months post-injection, and 80% at both 24 and 56 months. Infusion-related reactions occurred in 83% of the patients, primarily mild and transient; one patient required immunoglobulin supplementation but no severe infections were noted.

Conclusions: These preliminary results suggest that obinutuzumab is a promising first-line anti-CD20 therapy for FRNS and SDNS in children, offering sustained remission with a good safety profile.

查看原文本刊更多论文

Obinutuzumab作为儿科频繁复发和类固醇依赖性肾病综合征的主要抗cd20药物。

背景：特发性肾病综合征（INS）是儿童肾小球的主要疾病，通常类固醇治疗效果良好。然而，频繁复发性肾病综合征（FRNS）或类固醇依赖性肾病综合征（SDNS）需要引入类固醇保留剂来减轻类固醇毒性。方法：这项包括6例FRNS或SDNS患者的回顾性试点研究评估了obinutuzumab作为一线抗cd20治疗的有效性和安全性。结果：使用一剂obinutuzumab，所有6例患者在11个月内完全缓解。注射后12个月的缓解率为100%，24和56个月的缓解率均为80%。83%的患者发生了输液相关反应，主要是轻微和短暂的；1例患者需要补充免疫球蛋白，但未见严重感染。结论：这些初步结果表明，obinutuzumab是一种有希望的一线抗cd20治疗儿童FRNS和SDNS，提供持续缓解和良好的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Nephrology 医学-泌尿学与肾脏学

CiteScore

4.70

自引率

20.00%

发文量

465

审稿时长

1 months

期刊介绍： International Pediatric Nephrology Association Pediatric Nephrology publishes original clinical research related to acute and chronic diseases that affect renal function, blood pressure, and fluid and electrolyte disorders in children. Studies may involve medical, surgical, nutritional, physiologic, biochemical, genetic, pathologic or immunologic aspects of disease, imaging techniques or consequences of acute or chronic kidney disease. There are 12 issues per year that contain Editorial Commentaries, Reviews, Educational Reviews, Original Articles, Brief Reports, Rapid Communications, Clinical Quizzes, and Letters to the Editors.